In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Matchmaking And Integration In The New World Of Diagnostics M&A

Executive Summary

Nontraditional buyers, including Big Pharmas, life science tool companies, diversified conglomerates, and even food companies, are snapping up molecular diagnostics assets with increasing frequency, applying a variety of models to enhance their businesses.

Advertisement

Related Content

Diagnostics In 2016: From Alere To Zika
When Illumina Buys Roche: The Dawning Of The Era Of Diagnostics Dominance
Molecular Diagnostics M&A: Dormant But Not Done
Hologic Grabs Gen-Probe
Is Diagnostics the New Biotech...and Will Pharma Embrace It?
Nestle Gains GI Diagnostics For Nutritional Health Biz Via Prometheus Deal
With Genoptix, Novartis Continues Its Diagnostics Build-up
GE Acquires Clarient To Anchor Its Molecular IVD Business
Taking Stock Of Qiagen
Novartis Follows Its Own Business Development Model into Molecular Diagnostics

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

IV004022

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel